Catalyst Pharmaceuticals, based in Coral Gables, Florida, develops and commercializes novel medicines for rare diseases, including FIRDAPSE for Lambert-Eaton Myasthenic Syndrome and AGAMREE for Duchenne Muscular Dystrophy. The company, which went public in 2006, employs 167 people.
Brian Elsbernd sold 62,975 shares of CPRX on 3 March at $22.93 per share, worth a total of $1.4M. They now own 188,564 CPRX shares, or a 25% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
